Trifluridine/tipiracil hydrochloride is named as a drug or biological intervention in 2 clinical trials in our Ireland and China trial registers, none of which are currently recruiting. Lead sponsors include Institut de Recherches Internationales Servier (1) and Sir Run Run Shaw Hospital (1). Registered phases: Phase 3 and Phase 2. Conditions studied include Metastatic Colorectal Cancer; Rectal Adenocarcinoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06872606 | Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer (ClinicalTrials.gov ↗) Rectal Adenocarcinoma |
Phase 2 | Not yet open |
| NCT03869892 | Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. Metastatic Colorectal Cancer |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Metastatic Colorectal Cancer | 1 |
| Rectal Adenocarcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Institut de Recherches Internationales Servier | 1 |
| Sir Run Run Shaw Hospital | 1 |
| Register | Trifluridine/tipiracil hydrochloride trials |
|---|---|
| Clinical trials in Ireland | 1 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Trifluridine/tipiracil hydrochloride works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Trifluridine/tipiracil hydrochloride (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.